

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee Jul 2021 Meeting Outcome**

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Abatacept	Orencia	Musculoskeletal and joint disease	Approved	
2	Acalabrutinib	Calquence	Malignant disease and immunosuppression	Approved	
3	Agalsidase Alfa	Replagal	Nutrition and blood	Approved	
4	Atezolizumab / Bevacizumab	Tecentriq / Avastin	Malignant disease and immunosuppression	Pending	Pending further information
5	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Pending	Pending further information
6	Bevacizumab	Avastin	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
7	Brolucizumab	Beovu	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
8	Cabazitaxel	Jevtana	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
9	Cerebrolysin	Cerebrolysin	Cardiovascular system	Rejected	Lack of high quality level of evidence to demonstrate its efficacy
10	Dabrafenib / Trametinib	Tafinlar / Mekinist	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
11	Daratumumab	Darzalex	Malignant disease and immunosuppression	Pending	Pending further information
12	Darolutamide	Nubeqa	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
13	Dupilumab	Dupixent	Skin	Approved	
14	Efmoroctocog alfa	Eloctate	Cardiovascular system	Approved	
15	Entrectinib	Rozlytrek	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
16	Ibrutinib	Imbruvica	Malignant disease and immunosuppression	Approved	
17	Icatibant	Firazyr	Respiratory system	Approved	
18	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Approved	

	<b>Generic name</b>	<b>Brand name</b>	<b>Therapeutic Class</b>	<b>Meeting outcome</b>	<b>Primary reason for rejection<sup>1</sup></b>
19	Nicardipine hydrochloride	Nicardipine Aguetant	Cardiovascular system	Approved	
20	Nintedanib	Ofev	Respiratory system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
21	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
22	Pertuzumab	Perjeta	Malignant disease and immunosuppression	Approved	
23	Polatuzumab vedotin	Polivy	Malignant disease and immunosuppression	Pending	Pending further information
24	Ramucirumab	Cyramza	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
25	Ribociclib	Kisqali	Malignant disease and immunosuppression	Approved	
26	Riociguat	Adempas	Cardiovascular system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
27	Satralizumab	Enspryng	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
28	Sodium zirconium cyclosilicate	Lokelma	Nutrition and blood	Approved	
29	Talazoparib	Talzenna	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
30	Ticagrelor	Brilinta	Cardiovascular system	Approved	
31	Tiotropium	Spiriva Respimat	Respiratory system	Approved	

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.